| 14.23 0.87 (6.51%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.53 |
1-year : | 23.98 |
| Resists | First : | 17.57 |
Second : | 20.53 |
| Pivot price | 13.71  |
|||
| Supports | First : | 13.35 |
Second : | 10.75 |
| MAs | MA(5) : | 13.81 |
MA(20) : | 14.36 |
| MA(100) : | 15.17 |
MA(250) : | 14.54 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 47.6 |
D(3) : | 45.8 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 21.39 | Low : | 9.31 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TRDA ] has closed below upper band by 41.7%. Bollinger Bands are 64.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 14.47 - 14.54 | 14.54 - 14.61 |
| Low: | 12.56 - 12.63 | 12.63 - 12.69 |
| Close: | 14.11 - 14.23 | 14.23 - 14.35 |
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Wed, 29 Nov 2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA - PR Newswire
Mon, 27 Nov 2023
HC Wainwright Adjusts Entrada Therapeutics' Price Target to $20 From $25, Maintains Buy Rating - Marketscreener.com
Fri, 24 Nov 2023
How Will the Market React to Entrada Therapeutics Inc (TRDA) Stock Getting a Bearish Rating - InvestorsObserver
Thu, 23 Nov 2023
Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug - Yahoo Finance
Thu, 23 Nov 2023
EXEL: 3 Biotech Stocks to Buy to Help the Health of Your Portfolio - StockNews.com
Wed, 22 Nov 2023
Why Is Neuromuscular Disease Focused Entrada Therapeutics (TRDA) Shares Trading Lower Today? - Entrada Th - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 14.9 (%) |
| Held by Institutions | 74.9 (%) |
| Shares Short | 1,660 (K) |
| Shares Short P.Month | 1,650 (K) |
| EPS | -0.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.4 |
| Profit Margin | -25 % |
| Operating Margin | 32 % |
| Return on Assets (ttm) | -5.6 % |
| Return on Equity (ttm) | -9.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.61 |
| EBITDA (p.s.) | -0.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 117 (M) |
| Levered Free Cash Flow | 124 (M) |
| PE Ratio | -20.33 |
| PEG Ratio | 0 |
| Price to Book value | 1.92 |
| Price to Sales | 5.44 |
| Price to Cash Flow | 4.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|